Jens Kastrup

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4152353/publications.pdf

Version: 2024-02-01

124 papers	5,591 citations	87888 38 h-index	85541 71 g-index
124 all docs	124 docs citations	124 times ranked	6638 citing authors

#	Article	IF	Citations
1	Fiveâ€year followâ€up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATEâ€AMI trial. ESC Heart Failure, 2022, 9, 1152-1159.	3.1	8
2	Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II). Stem Cells Translational Medicine, 2022, 11, 478-489.	3.3	16
3	GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use. Stem Cells International, 2022, 2022, 1-12.	2.5	7
4	Adipose-derived stromal cells increase the formation of collagens through paracrine and juxtacrine mechanisms in a fibroblast co-culture model utilizing macromolecular crowding. Stem Cell Research and Therapy, 2022, 13, .	5.5	3
5	Cryopreservation of peripheral blood mononuclear cells for use in proliferation assays: First step towards potency assays. Journal of Immunological Methods, 2021, 488, 112897.	1.4	7
6	Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease. Ocular Surface, 2021, 19, 43-52.	4.4	39
7	Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. Cardiovascular Research, 2021, 117, 1428-1433.	3.8	20
8	Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. European Heart Journal, 2021, 42, 228-239.	2.2	50
9	Myocardial CT perfusion compared with transthoracic Doppler echocardiography in evaluation of the coronary microvascular function: An iPOWER substudy. Clinical Physiology and Functional Imaging, 2021, 41, 85-94.	1.2	2
10	Impaired coronary flow velocity reserve is associated with cardiovascular risk factors but not with angina symptoms. Open Heart, 2021, 8, e001486.	2.3	4
11	Proteoglycan Remodeling Is Accelerated in Females with Angina Pectoris and Diffuse Myocardial Fibrosis: the iPOWER Study. Journal of Cardiovascular Translational Research, 2021, 14, 921-929.	2.4	0
12	Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. ESC Heart Failure, 2021, 8, 2306-2309.	3.1	13
13	A screening method to spot biomarkers that may warn of serious events in a chronic diseaseÂâ€“ illustrated by cardiological CLARICOR trial data. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1852-1860.	2.3	0
14	Diagnostic performance of a new ECG algorithm for reducing false positive cases in patients suspected acute coronary syndrome. Journal of Electrocardiology, 2021, 69, 60-64.	0.9	2
15	The Initial Cardiac Tissue Response to Cryopreserved Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells in Rats with Chronic Ischemic Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 11758.	4.1	5
16	Bone marrowâ€derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4â€year followâ€up of the MSCâ€HF trial. European Journal of Heart Failure, 2020, 22, 884-892.	7.1	86
17	Inflammation, non-endothelial dependent coronary microvascular function and diastolic functionâ€”Are they linked?. PLoS ONE, 2020, 15, e0236035.	2.5	19
18	The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. European Heart Journal, 2020, 41, 3702-3710.	2.2	47

#	Article	IF	Citations
19	Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review. Biomedicines, 2020, 8, 570.	3.2	11
20	Adipose Tissue-Derived Stromal Cells Induce a Highly Trophic Environment While Reducing Maturation of Monocyte-Derived Dendritic Cells. Stem Cells International, 2020, 2020, 1-12.	2.5	7
21	Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Upâ€"A CLARICOR Trial Sub-Study. Journal of Clinical Medicine, 2020, 9, 265.	2.4	7
22	The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. Transplant International, 2020, 33, 833-840.	1.6	15
23	Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy. Atherosclerosis, 2020, 301, 8-14.	0.8	9
24	Cardiac Magnetic Resonance Imaging used for Evaluation of Adipose-Derived Stromal Cell Therapy in Patients with Chronic Ischemic Heart Disease. Cell Transplantation, 2019, 28, 1700-1708.	2.5	5
25	Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results. Journal of Translational Medicine, 2019, 17, 360.	4.4	28
26	Overlap between angina without obstructive coronary artery disease and left ventricular diastolic dysfunction with preserved ejection fraction. PLoS ONE, 2019, 14, e0216240.	2.5	8
27	Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. IJC Heart and Vasculature, 2019, 24, 100370.	1.1	26
28	Coronary microvascular dysfunction is associated with cardiac time intervals in women with angina and no obstructive coronary artery disease: An iPOWER substudy. Echocardiography, 2019, 36, 1110-1117.	0.9	5
29	Myocardial first pass perfusion assessed by cardiac magnetic resonance and coronary microvascular dysfunction in women with angina and no obstructive coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 238-246.	1.2	14
30	Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Nonâ€treatable Cardiac diseasE (SCIENCE). European Journal of Heart Failure, 2019, 21, 1032-1041.	7.1	36
31	In Vivo MRI Tracking of Mesenchymal Stromal Cells Labeled with Ultrasmall Paramagnetic Iron Oxide Particles after Intramyocardial Transplantation in Patients with Chronic Ischemic Heart Disease. Stem Cells International, 2019, 2019, 1-10.	2.5	18
32	Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovascular Research, 2019, 115, 1519-1532.	3.8	25
33	Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 293-300.	1.2	42
34	Accelerated collagen turnover in women with angina pectoris without obstructive coronary artery disease: An iPOWER substudy. European Journal of Preventive Cardiology, 2018, 25, 719-727.	1.8	19
35	YKL-40 in patients with end-stage renal disease receiving haemodialysis. Biomarkers, 2018, 23, 357-363.	1.9	14
36	10â€Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Association, 2018, 7, .	3.7	33

#	Article	IF	Citations
37	Ventricular repolarization alterations in women with angina pectoris and suspected coronary microvascular dysfunction. Journal of Electrocardiology, 2018, 51, 15-20.	0.9	4
38	Coronary microvascular dysfunction and myocardial contractile reserve in women with angina and no obstructive coronary artery disease. Echocardiography, 2018, 35, 196-203.	0.9	33
39	Electrocardiographic scores of severity and acuteness of myocardial ischemia predict myocardial salvage in patients with anterior ST-segment elevation myocardial infarction. Journal of Electrocardiology, 2018, 51, 195-202.	0.9	6
40	Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course. Open Heart, 2018, 5, e000808.	2.3	7
41	Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. Atherosclerosis, 2018, 278, 97-102.	0.8	22
42	Protein biomarkers and coronary microvascular dilatation assessed by rubidium-82 PET in women with angina pectoris and no obstructive coronary artery disease. Atherosclerosis, 2018, 275, 319-327.	0.8	15
43	Retention and Functional Effect of Adipose-Derived Stromal Cells Administered in Alginate Hydrogel in a Rat Model of Acute Myocardial Infarction. Stem Cells International, 2018, 2018, 1-13.	2.5	12
44	Angiogenesis PET Tracer Uptake (68Ga-NODAGA-E[(cRGDyK)]2) in Induced Myocardial Infarction and Stromal Cell Treatment in Minipigs. Diagnostics, 2018, 8, 33.	2.6	8
45	Automatic electrocardiographic algorithm for assessing severity of ischemia in ST-segment elevation myocardial infarction. International Journal of Cardiology, 2018, 268, 18-22.	1.7	2
46	Semiâ€quantitative myocardial perfusion measured by computed tomography in patients with refractory angina: a headâ€toâ€head comparison with quantitative rubidiumâ€82 positron emission tomography as reference. Clinical Physiology and Functional Imaging, 2017, 37, 481-488.	1.2	4
47	Transthoracic Doppler echocardiography compared with positron emission tomography for assessment of coronary microvascular dysfunction: The iPOWER study. International Journal of Cardiology, 2017, 228, 435-443.	1.7	43
48	Prehospital electrocardiographic acuteness score of ischemia is inversely associated with neurohormonal activation in STEMI patients with severe ischemia. Journal of Electrocardiology, 2017, 50, 90-96.	0.9	5
49	The effect of intracoronary infusion of bone marrowâ€derived mononuclear cells on allâ€cause mortality in acute myocardial infarction: rationale and design of the <scp>BAMI</scp> trial. European Journal of Heart Failure, 2017, 19, 1545-1550.	7.1	45
50	Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failureâ€”A Safety Study. Stem Cells Translational Medicine, 2017, 6, 1963-1971.	3.3	80
51	Influence of patient related factors on number of mesenchymal stromal cells reached after in vitro culture expansion for clinical treatment. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 541-548.	1.2	7
52	Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137	1.8	12
53	Comparison of rest and adenosine stress quantitative and semi-quantitative myocardial perfusion using magnetic resonance in patients with ischemic heart disease. Clinical Imaging, 2017, 41, 149-156.	1.5	3
54	Algorithm for the automatic computation of the modified Andersonâ€“Wilkins acuteness score of ischemia from the pre-hospital ECG in ST-segment elevation myocardial infarction. Journal of Electrocardiology, 2017, 50, 97-101.	0.9	4

#	Article	IF	Citations
55	Senescence and quiescence in adipose-derived stromal cells: Effects of human platelet lysate, fetal bovine serum and hypoxia. Cytotherapy, 2017, 19, 95-106.	0.7	21
56	Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study. Stem Cells International, 2017, 2017, 1-8.	2.5	22
57	Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study. Stem Cells International, 2017, 2017, 1-12.	2.5	38
58	Global position paper on cardiovascular regenerative medicine. European Heart Journal, 2017, 38, 2532-2546.	2.2	133
59	Cardiovascular magnetic resonance imaging of myocardial oedema following acute myocardial infarction: Is whole heart coverage necessary?. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 7.	3.3	11
60	Angiogenesis PET Tracer Uptake (68Ga-NODAGA-E[(cRGDyK)]2) in Induced Myocardial Infarction in Minipigs. Diagnostics, 2016, 6, 26.	2.6	6
61	Mesenchymal stromal cell therapy in ischemic heart disease. Scandinavian Cardiovascular Journal, 2016, 50, 293-299.	1.2	9
62	The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. Cardiovascular Endocrinology, 2016, 5, 21-27.	0.8	4
63	Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. Journal of Translational Medicine, 2016, 14, 319.	4.4	49
64	Myocardial perfusion of infarcted and normal myocardium in propofol-anesthetized minipigs using 82Rubidium PET. Journal of Nuclear Cardiology, 2016, 23, 599-603.	2.1	5
65	Coronary Flow Velocity Reserve Assessed by Transthoracic Doppler: The iPOWER Study: FactorsÂInfluencing Feasibility and Quality. Journal of the American Society of Echocardiography, 2016, 29, 709-716.	2.8	50
66	Cryopreservation and Revival of Human Mesenchymal Stromal Cells. Methods in Molecular Biology, 2016, 1416, 357-374.	0.9	19
67	Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study. Journal of the American Heart Association, 2016, 5, e003064.	3.7	131
68	Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 93-104.	1.2	42
69	Increased Paracrine Immunomodulatory Potential of Mesenchymal Stromal Cells in Three-Dimensional Culture. Tissue Engineering - Part B: Reviews, 2016, 22, 322-329.	4.8	106
70	Pre-hospital electrocardiographic severity and acuteness scores predict left ventricular function in patients with ST elevation myocardial infarction. Journal of Electrocardiology, 2016, 49, 284-291.	0.9	6
71	Evaluation of acute ischemia in pre-procedure ECG predicts myocardial salvage after primary PCI in STEMI patients with symptoms >12hours. Journal of Electrocardiology, 2016, 49, 278-283.	0.9	10
72	A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial. European Heart Journal, 2016, 37, 256-263.	2.2	88

#	Article	IF	Citations
73	Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 76.	3.3	30
74	Experimental myocardial stem cell therapy for ST-elevation myocardial infarction: rationale and level of evidence. Minerva Cardioangiologica, 2016, 64, 322-9.	1.2	1
75	Influence of vascular endothelial growth factor stimulation and serum deprivation on gene activation patterns of human adipose tissue-derived stromal cells. Stem Cell Research and Therapy, 2015, 6, 62.	5.5	25
76	Human adipose-derived stromal cells in a clinically applicable injectable alginate hydrogel: Phenotypic and immunomodulatory evaluation. Cytotherapy, 2015, 17, 1104-1118.	0.7	49
77	Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). European Heart Journal, 2015, 36, 1744-1753.	2.2	276
78	Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology, 2015, 182, 459-465.	1.7	67
79	Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data. Circulation Research, 2015, 116, 1346-1360.	4.5	270
80	Revival of cytokine therapy in heart failure?. European Heart Journal, 2015, 36, 3070-3073.	2.2	2
81	Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. European Journal of Preventive Cardiology, 2014, 21, 1275-1284.	1.8	22
82	Ultrastructural characterization of mesenchymal stromal cells labeled with ultrasmall superparamagnetic iron-oxide nanoparticles for clinical tracking studies. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 437-446.	1.2	12
83	Quantification of myocardial perfusion using cardiac magnetic resonance imaging correlates significantly to rubidium-82 positron emission tomography in patients with severe coronary artery disease: A preliminary study. European Journal of Radiology, 2014, 83, 1120-1128.	2.6	16
84	Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial. American Heart Journal, 2014, 168, 197-204.e4.	2.7	34
85	Improving diagnosis and treatment of women with angina pectoris and microvascular disease: The iPOWER study design and rationale. American Heart Journal, 2014, 167, 452-458.	2.7	44
86	Short- and Long-Term Cause of Death inÂPatients Treated With Primary PCI forÂSTEMI. Journal of the American College of Cardiology, 2014, 64, 2101-2108.	2.8	301
87	Stem Cell Therapy to Treat Heart Ischaemia: Implications for Diabetes Cardiovascular Complications. Current Diabetes Reports, 2014, 14, 554.	4.2	8
88	The influence of contrast media on kidney function in patients with stable coronary artery disease. Scandinavian Cardiovascular Journal, 2014, 48, 234-240.	1.2	0
89	Identification of a common reference gene pair for qPCR in human mesenchymal stromal cells from different tissue sources treated with VEGF. BMC Molecular Biology, 2014, 15, 11.	3.0	32
90	Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. American Heart Journal, 2014, 168, 88-95.e2.	2.7	238

#	Article	IF	Citations
91	Abstract 15094: Prevalence of Coronary Microvascular Dysfunction in Women With Angina and No Obstructive Coronary Artery Disease: Preliminary Results From the iPower Study. Circulation, 2014, 130, .	1.6	0
92	Abstract 13781: Assessment of Microvascular Dysfunction by Transthoracic Echocardiography Compared to Positron Emission Tomography. Circulation, 2014, 130, .	1.6	0
93	Value of cardiac 320-multidetector computed tomography and cardiac magnetic resonance imaging for assessment of myocardial perfusion defects in patients with known chronic ischemic heart disease. International Journal of Cardiovascular Imaging, 2013, 29, 1585-1593.	1.5	18
94	Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina â€" Final 3-year follow-up. International Journal of Cardiology, 2013, 170, 246-251.	1.7	59
95	Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease. Journal of Translational Medicine, 2013, 11, 219.	4.4	26
96	Mesenchymal Stromal Cell Phenotype is not Influenced by Confluence during Culture Expansion. Stem Cell Reviews and Reports, 2013, 9, 44-58.	5.6	19
97	The Origin of Human Mesenchymal Stromal Cells Dictates Their Reparative Properties. Journal of the American Heart Association, 2013, 2, e000253.	3.7	41
98	Optimal Labeling Dose, Labeling Time, and Magnetic Resonance Imaging Detection Limits of Ultrasmall Superparamagnetic Iron-Oxide Nanoparticle Labeled Mesenchymal Stromal Cells. Stem Cells International, 2013, 2013, 1-10.	2.5	22
99	Direct Intramyocardial Mesenchymal Stromal Cell Injections in Patients with Severe Refractory Angina: One-Year Follow-Up. Cell Transplantation, 2013, 22, 521-528.	2.5	54
100	Non-invasive In-Vivo Imaging of Stem Cells after Transplantation in Cardiovascular Tissue. Theranostics, 2013, 3, 561-572.	10.0	22
101	Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regenerative Medicine, 2012, 7, 421-428.	1.7	105
102	Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). American Heart Journal, 2012, 164, 285-291.	2.7	86
103	Coronary artery stent mimicking intracardiac thrombus on cardiac magnetic resonance imaging due to signal loss: case report. Magnetic Resonance Imaging, 2012, 30, 889-892.	1.8	1
104	Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?. Immunobiology, 2012, 217, 483-491.	1.9	79
105	Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scandinavian Cardiovascular Journal, 2011, 45, 161-168.	1.2	69
106	Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome?. EPMA Journal, 2011, 2, 107-117.	6.1	23
107	Comparison of mesenchymal stromal cells from young healthy donors and patients with severe chronic coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 193-202.	1.2	16
108	A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention, 2011, 6, 813-818.	3.2	75

#	Article	IF	Citations
109	Gene therapy and angiogenesis in patients with coronary artery disease. Expert Review of Cardiovascular Therapy, 2010, 8, 1127-1138.	1.5	21
110	High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal, 2009, 30, 1066-1072.	2.2	148
111	Mesenchymal stromal cell and mononuclear cell therapy in heart disease. Future Cardiology, 2008, 4, 481-494.	1.2	7
112	Short- and long-term changes in myocardial function, morphology, edema, and infarct mass after ST-segment elevation myocardial infarction evaluated by serial magnetic resonance imaging. American Heart Journal, 2007, 154, 929-936.	2.7	70
113	Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. European Heart Journal, 2006, 27, 1785-1792.	2.2	136
114	Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy?. European Heart Journal, 2006, 27, 2748-2754.	2.2	37
115	Stem Cell Mobilization Induced by Subcutaneous Granulocyte-Colony Stimulating Factor to Improve Cardiac Regeneration After Acute ST-Elevation Myocardial Infarction. Circulation, 2006, 113, 1983-1992.	1.6	331
116	Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. International Journal of Cardiology, 2005, 100, 477-483.	1.7	86
117	Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectoris. Journal of the American College of Cardiology, 2005, 45, 982-988.	2.8	436
118	Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?. Current Gene Therapy, 2003, 3, 197-206.	2.0	39
119	Cardiovascular and neuroendocrine responses to water immersion in compensated heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1931-H1940.	3.2	40
120	Exercise blood flow and microvascular distensibility in skeletal muscle normalize after heart transplantation. Clinical Transplantation, 1999, 13, 410-419.	1.6	3
121	Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovascular Research, 1996, 32, 1148-1154.	3.8	61
122	Intravenous lidocaine infusion â€" a new treatment of chronic painful diabetic neuropathy?. Pain, 1987, 28, 69-75.	4.2	270
123	Chronic pain treatment with intravenous lidocaine. Neurological Research, 1986, 8, 189-190.	1.3	48
124	Effect of ganglionic blockade on endogenous circulating pancreatic polypeptide, vasoactive intestinal polypeptide, substance P, neurotensin and noradrenaline in healthy controls and long-term insulin-dependent diabetic patients. Clinical Science, 1986, 71, 411-419.	4.3	4